subject: Prospects for cureently antitubercular drugs [print this page] 1. World Health Organisation: Global Tuberculosis Control:Surveillance, Planning, Financing. WHO Report 2004.ISBN 92 4 156264 1. 2004. Geneva, Switzerland.2. Corbett EL, Watt CJ, Walker N, Maher D, Williams BG,Raviglione MC, Dye C: The growing burden of tuberculosis:global trends and interactions with the HIV epidemic.Arch Intern Med 2003, 163:1009-1021.3. Espinal MA: The global situation of MDR-TB. Tuberculosis 2003,83:44-51.4. O'Brien RJ, Nunn PP: The need for new drugs againsttuberculosis. Obstacles, opportunities, and next steps.Am J Respir Crit Care Med 2001, 163:1055-1058.5. Global Alliance for TB Drug Development: Tuberculosis.Scientific blueprint for tuberculosis drug development.Tuberculosis 2001, 81(Suppl 1):152.6. Benator D, Bhattacharya M, Bozeman L, Burman W, Cantazaro A,Chaisson R, Gordin F, Horsburgh CR, Horton J, Khan A et al.:Rifapentine and isoniazid once a week versus rifampicin andisoniazid twice a week for treatment of drug-susceptiblepulmonary tuberculosis in HIV-negative patients: arandomised clinical trial. Lancet 2002, 360:528-534.7. Weiner M, Burman W, Vernon A, Benator D, Peloquin CA,Khan A, Weis S, King B, Shah N, Hodge T et al.: Low isoniazidconcentrations and outcome of tuberculosis treatmentwith once-weekly isoniazid and rifapentine. Am J RespirCrit Care Med 2003, 167:1341-1347.8. Dietze R, Teixeira L, Rocha LM, Palaci M, Johnson JL, Wells C,Rose L, Eisenach K, Ellner JJ: Safety and bactericidal activity ofrifalazil in patients with pulmonary tuberculosis. AntimicrobAgents Chemother 2001, 45:1972-1976.
